Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models
Retrieved on:
Wednesday, September 7, 2022
Molecular imaging, PET, ADEM, Cancer, Research, Time of flight, Degenerative disease, Brain, Deoxycytidine kinase, Science, Multiple sclerosis, DCK, CyTOF, Pediatrics, DNA, EAE, Orphan drug, National, Immunology, GLOBE, National academy, Cytometry, Company, FDA, Stanford University, UCLA, MS, COVID-19, Optic neuritis, Private Securities Litigation Reform Act, Patient, Pharmaceutical industry, Medical imaging
TRE-515 is a clinical stage drug being developed by Trethera that targets the enzyme deoxycytidine kinase (dCK) in the deoxyribonucleoside salvage pathway.
Key Points:
- TRE-515 is a clinical stage drug being developed by Trethera that targets the enzyme deoxycytidine kinase (dCK) in the deoxyribonucleoside salvage pathway.
- Their results demonstrated that dCK activity is necessary for the development of clinical symptoms in both EAE models of MS.
- Targeting dCK with TRE-515 limited disease severity when treatments were started prophylactically at disease induction or therapeutically after symptoms appear.
- (2022), Targeting deoxycytidine kinase improves symptoms in mouse models of multiple sclerosis.